27 completed, 2 active not recruiting, 1 enrolling by invitation. 13 Phase 2, 12 Phase 1, 3 Phase 3, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 13 |
| Phase 1 | 12 | Completed 12 |
| Phase 3 | 3 | Completed 2, Active not recruiting 1 |
| Not applicable | 1 | Enrolling by invitation 1 |
| Phase 4 | 1 | Active not recruiting 1 |
Follow Avian Influenza: new trials by email Literature Review of Avian Influenza trials Research Report on Avian Influenza
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Smart Analysis and Decision-Making for Emerging Infectious Diseases Multi-Agent Integrated Smart Toolkit for Emerging Infectious Diseases, Routine Practices - Emerging Infectious Diseases, COVID-19 | Not applicable | Enrolling by invitation | Peking University | 108 | 2026-08-10 | 2026-08-19 |
| Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial) H5N1 vaccine (Arepanrix, GSK), Placebo - Influenza (Pandemic), Avian Influenza | Phase 3 | Active not recruiting | University Health Network, Toronto | 120 | 2025-11-03 | 2026-10-23 |
| Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart H5N1 vaccine (Arepanrix), Saline (as a placebo) - H5N1 Influenza, H5N1 Virus | Phase 4 | Active not recruiting | Canadian Immunization Research Network | 312 | 2025-10-14 | 2026-01-16 |
| A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults H5 AC-Anhui RNA Vaccine, H5 Astrakhan RNA Vaccine, Sodium Chloride, 0.9% - Avian Influenza | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 80 | 2025-06-12 | 2026-06-12 |
| 2017 A/H7N9 IIV Revaccination A/H7N9, AS03, Phosphate Buffered Saline (PBS) diluent - Avian Influenza, Influenza Immunisation | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 304 | 2018-12-18 | 2021-07-30 |
| Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza A/H7N9, MF59, Phosphate Buffered Saline (PBS) diluent - Avian Influenza, Influenza Immunisation | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 372 | 2018-11-02 | 2021-05-17 |
| 2013/2017 H7N9 Prime-Boost Interval A/H7N9, AS03, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013 - Avian Influenza, Influenza Immunisation | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 180 | 2018-08-21 | 2021-08-02 |
| H5N1 With or Without Topical Aldara in Healthy Adults Aqueous Cream B.P., Imiquimod, Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04 - Avian Influenza, Influenza Immunisation | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 50 | 2018-06-13 | 2020-02-24 |
| Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4 AS03, Inactivated influenza H7N9 vaccine, Influenza Virus Quadrivalent Inactivated Vaccine - Avian Influenza, Influenza | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 149 | 2018-02-20 | 2020-08-06 |
| Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly AS03, Inactivated influenza H7N9 vaccine, Phosphate Buffered Saline (PBS) diluent - Avian Influenza, Influenza Immunisation | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 720 | 2018-02-14 | 2024-09-19 |
| A Safety and Immunogenicity Study of IVACFLU-A/H5N1 IVACFLU-A/H5N1 vaccine, Placebo - Avian Influenza | Phase 2 / Phase 3 | Completed | Institute of Vaccines and Medical Biologicals, Vietnam | 930 | 2017-03-07 | 2019-05-21 |
| H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology AS03, MF59, Monovalent Influenza A/H5N8 vaccine - Avian Influenza | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 388 | 2017-01-09 | 2024-09-23 |
| H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses AS03, Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203, Monovalent influenza A/H7N9 virus vaccine - Avian Influenza, H1N1 Influenza | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2016-11-07 | 2024-10-09 |
| H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults AS03, MF59 adjuvant, Monovalent Influenza A/H5N8 vaccine - Avian Influenza, Influenza | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 276 | 2016-08-16 | 2019-10-23 |
| A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age aH5N1c, Placebo - Avian Influenza | Phase 3 | Completed | Seqirus | 3196 | 2016-07-11 | 2024-12-06 |
| A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, MF59 adjuvant - Avian Influenza, Immunisation | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 62 | 2015-05-18 | 2020-01-27 |
| H7N9 Mix and Match With MF59 in Healthy Elderly Persons MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013 - Avian Influenza | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 479 | 2014-10-01 | 2017-07-06 |
| Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine OrniFlu® inactivated vaccine - Avian Influenza | Phase 2 | Completed | Mahidol University | 60 | 2014-06-01 | 2015-04-09 |
| A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1 Monovalent Avian Influenza VLP (H7N9), Adjuvant 1, Placebo - Avian Influenza | Phase 1 | Completed | Novavax | 280 | 2013-07-01 | 2014-10-13 |
| Safety and Pharmacokinetics Study of FBF001 FBF001, Placebo - Avian Influenza | Phase 1 | Completed | Fab'entech | 16 | 2012-10-01 | 2014-11-20 |
Showing 20 of 30. Sign in to see all of them.
Influenza in Birds (30) · Influenza, Human (19) · COVID-19 (1) · Chikungunya Fever (1) · Communicable Diseases, Emerging (1) · Dengue (1) · Dyspnea (1) · Mpox, Monkeypox (1) · Orthomyxoviridae Infections (1) · Virus Diseases (1)
Animal Diseases (30) · Bird Diseases (30) · Infections (30) · RNA Virus Infections (30) · Orthomyxoviridae Infections (29) · Virus Diseases (29) · Respiratory Tract Diseases (19) · Respiratory Tract Infections (19) · Pathological Conditions, Signs and Symptoms (2) · Alphavirus Infections (1) · Arbovirus Infections (1) · Communicable Diseases (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · DNA Virus Infections (1)
Influenza Vaccines (6) · MF59 oil emulsion (3) · Sodium Chloride (3) · arepanrix (2) · Imiquimod (1) · Oseltamivir (1) · Saline Solution (1) · halofantrine (1)
National Institute of Allergy and Infectious Diseases (NIAID) (13) · St. Jude Children's Research Hospital (2) · Vaxart (2) · Alachua Government Services, Inc. (1) · Canadian Immunization Research Network (1) · Fab'entech (1) · Institute of Vaccines and Medical Biologicals, Vietnam (1) · Mahidol University (1) · Medigen Biotechnology Corporation (1) · Novartis (1) · Novartis Vaccines (1) · Novavax (1) · PATH (1) · Peking University (1) · Seqirus (1)
United States (16) · Canada (2) · Thailand (2) · Vietnam (2) · Australia (1) · Austria (1) · China (1) · Colombia (1) · Egypt (1) · Finland (1) · Italy (1) · Lebanon (1) · Russia (1) · Singapore (1) · Taiwan (1)
D. Nigel Thomas, Ph.D. (1) · David Liebowitz, MD, PhD (1) · Gerald Aichinger, MD (1) · Ghazi Kayali, Ph.D (1) · Igor Victorevich (1) · Joanne M Langley (1) · Jue Liu, Doctor (1) · Kathleen M Neuzil, MD, MPH (1) · Larisa G Rudenko, MD, PhD, DSc (1) · Martin Kabongo, MD, PhD (1) · Mohammad Ghazi Kayali, Ph.D, MPH (1) · Oleg I Kiselev, MD, PhD, DSc (1)
PMID 39756216, PMID 20810680, PMID 21606530, PMID 23357198, PMID 23536690, PMID 23723457, PMID 24224560, PMID 24533064, PMID 25662592, PMID 26432909, PMID 28533093, PMID 31255574, PMID 31812464, PMID 33852718, PMID 35455245, PMID 35465983, PMID 37466221, PMID 38537255, PMID 39798434, PMID 42630599
N01AI70005 (1)